Psychedelic Medicine – Charles S. Grob, Stephen Ross, Matthew W. Johnson, and Mark J. Plotkin
Psychedelic Medicine: The New Science of Hallucinogens
Friday, October 16, 2015
Charles S. Grob, MD, Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center; Matthew W. Johnson, PhD, Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine; and Stephen Ross, MD, Associate Professor of Psychiatry and Child & Adolescent Psychiatry at New York University School of Medicine, Director of the Division of Alcoholism and Drug Abuse, the Dual Diagnosis Training Unit and the Opioid Overdose Prevention Program at Bellevue Hospital Center, and Director of the NYU Psychedelic Research Group
Introduction by Mark J. Plotkin, PhD, ethnobotanist; Founder and President of The Amazon Conservation Team; and author of Tales of a Shaman’s Apprentice and Medicine Quest
For over forty years, drugs like LSD and psilocybin (the active ingredient in “magic” mushrooms) were classified as the most dangerous, Schedule I substances, with no accepted medical use. They were impossible to secure for research, but recently, that began to change. These and other psychedelic compounds are capturing attention again —not as part of a trippy counter-culture, but as an exciting new frontier in medicine. Can we unlock their powerful potential to help patients gripped by depression, struggling with terminal cancer, or craving another cigarette? Venture on a trip with the researchers exploring groundbreaking treatments for addiction, PTSD, and end-of-life anxiety.
This program is free thanks to the generosity of the Lowell Institute.